Noda-Narita, Shoko
Shimomura, Akihiko
Kawachi, Asuka
Sumiyoshi-Okuma, Hitomi
Sudo, Kazuki
Shimoi, Tatsunori
Noguchi, Emi
Yonemori, Kan
Shimizu, Chikako
Fujiwara, Yasuhiro
Tamura, Kenji
Article History
Received: 1 December 2018
Accepted: 18 January 2019
First Online: 8 February 2019
Compliance with ethical standards
:
: S.Narita has nothing to disclose; A Shimomura reports lecture fees from Chugai Pharmatheutical, grants and lecture fees from Novartis Pharmatheutical, lecture fees from Pfizer, lecture fees from Nippon Kayaku, lecture fees and advisory board from AstraZeneca, lecture fees from Eisai, outside the submitted work; A Kawachi, H Okuma, K Sudo, T Shimoi and E Noguchi has nothing to disclose; K Yonemori reports lecture fees from Eisai, lecture fees from Taiho, lecture fees from Novartis, outside the submitted work; C Shimizu reports grants from Eli-Lilly, lecture fees from Chugai, lecture fees from Pfizer, lecture fees from Astra Zeneca, lecture fees from Eizai, lecture fees from Daiichi Sankyo, outside the submitted work; Y Fujiwara reports lecture fees from Astra Zeneca KK, lecture fees from Eisai Co., Ltd, lecture fees from Daiichi Sankyo Co., Ltd, lecture fees from Taiho Pharmaceutical Co., Ltd, grants from Takeda Pharmaceutical Co., Ltd, grants and lecture fees from Chugai Pharmaceutical Co., Ltd, lecture fees from Eli Lilly Japan KK, lecture fees from Novartis Pharma KK, outside the submitted work; K Tamura has nothing to disclose.
: The present study was approved by the NCCH Institutional Review Board and was conducted in accordance with the ethical standards of the institutional and national research committee.
: All procedures performed in studies involving human participants were in accordance the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was waived owing to the retrospective nature of the study.